W V Crandall1, L M Mackner. 1. Section of Pediatric Gastroenterology and Nutrition, Columbus Children's Hospital, 700 Children's Drive, Columbus, OH 43205-2696, USA. crandallw@pediatrics.ohio-state.edu
Abstract
BACKGROUND: Crohn's disease commonly affects children and adolescents, however the majority of research into the safety and efficacy of therapies for inflammatory bowel disease, including infliximab, has occurred only in adults. AIM: To determine the rate of reactions in children following infliximab infusions, and to identify variables that might be predictive of those reactions. METHODS: We performed a retrospective review of all infliximab infusions performed at Columbus Children's Hospital from December 1998 through September 2001. RESULTS: Fifty-seven children received 361 infusions. Three hundred and fifty-five of the 361 infusions (98.3%) were completed. Fifty children had 304 repeat infusions. There were a total of 35 infusion related reactions. Female gender and the use of immunosuppressive medications for less than 4 months were risk factors for a reaction to infusion number 2. A reaction to infusion 2 and immunosuppressive use for less than 4 months were risk factors for infusion number 3. CONCLUSIONS: The rate of infusion reactions in children receiving infliximab is similar to that in adults. Female gender, immunosuppressive use for less than 4 months and prior infusion reactions may be risk factors for subsequent infusion reactions in children.
BACKGROUND:Crohn's disease commonly affects children and adolescents, however the majority of research into the safety and efficacy of therapies for inflammatory bowel disease, including infliximab, has occurred only in adults. AIM: To determine the rate of reactions in children following infliximab infusions, and to identify variables that might be predictive of those reactions. METHODS: We performed a retrospective review of all infliximab infusions performed at Columbus Children's Hospital from December 1998 through September 2001. RESULTS: Fifty-seven children received 361 infusions. Three hundred and fifty-five of the 361 infusions (98.3%) were completed. Fifty children had 304 repeat infusions. There were a total of 35 infusion related reactions. Female gender and the use of immunosuppressive medications for less than 4 months were risk factors for a reaction to infusion number 2. A reaction to infusion 2 and immunosuppressive use for less than 4 months were risk factors for infusion number 3. CONCLUSIONS: The rate of infusion reactions in children receiving infliximab is similar to that in adults. Female gender, immunosuppressive use for less than 4 months and prior infusion reactions may be risk factors for subsequent infusion reactions in children.
Authors: R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey Journal: Gut Date: 2006-03 Impact factor: 23.059
Authors: Jia-Qi Li; Jie Chen; Nan-Nan Liu; Li Yang; Ying Zeng; Bin Wang; Xue-Rong Wang Journal: World J Gastroenterol Date: 2011-04-28 Impact factor: 5.742
Authors: Min Seob Song; Sang Bum Lee; Sejung Sohn; Jin Hee Oh; Kyung Lim Yoon; Ji Whan Han; Chul Ho Kim Journal: Korean Circ J Date: 2010-07-26 Impact factor: 3.243